>
Feb. 14: Carol Symes, associate professor and associate chair of history and director of graduate studies at Illinois, will discuss “Historical Perspectives of Pandemics.” Past and recent waves of disease have influenced the cultures of the world, from the Antonine plague that decimated the Roman army, through the bubonic plague that reshaped Europe and the world in the 14th century, to the current COVID-19 pandemic.
>
Feb. 21: Dr. Ali S. Khan, dean of the College of Public Health and professor of epidemiology at UNMC, will discuss “Threats to Global Health and the Role of the World Health Organization.” Current news coverage focuses on local and national issues, but pandemics affect the world. The WHO monitors and coordinates responses to disease outbreaks that threaten to become deadly pandemics.
The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV.
22 Jan 2021 / 20:02 H.
(For more Reuters Special Reports, click on)
By Ned Parker and Chad Terhune
Jan 22 (Reuters) - In early February, 57 people arrived at a Nebraska military base, among the first Americans evacuated from Wuhan, China, the epicenter of the new coronavirus outbreak. U.S. health officials knew very little then about the mysterious new virus, and the quarantined group offered an early opportunity to size up the threat.
The federal government sought help from a team at the University of Nebraska Medical Center, including Dr. James Lawler, an experienced infectious disease specialist. Lawler told Reuters he immediately asked the world-renowned U.S. Centers for Disease Control and Prevention (CDC) for permission to test the quarantined group, deeming it crucial to know whether people without symptoms were infected and could spread the deadly pathogen.
COVID-19 timeline: It s been one year since the first announced case in the United States
Hearst Television
FacebookTwitterEmail
Jan. 20, 2020
Jan. 21, 2020
Jan. 29, 2020
The White House announces the formation of a new task force that will help monitor and contain the spread of the virus, and ensure Americans have accurate and up-to-date health and travel information, it says.
Jan. 30, 2020
The United States reports its first confirmed case of person-to-person transmission of the coronavirus. On the same day, WHO determines that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).
Jan. 31, 2020
The Trump administration announces it will deny entry to foreign nationals who have traveled in China in the last 14 days.
Share this article
Share this article
TITUSVILLE, N.J., Jan. 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen s rilpivirine and ViiV Healthcare s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.
CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resist